Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:      
Net loss $ (24,774) $ (38,371) $ (44,434)
Adjustments to reconcile net loss to cash used in operating activities:      
Depreciation 30 31 84
Amortization 254 1,719 1,716
Lease termination adjustments   473  
Share-based compensation expense 363 784 4,758
Cancellation of share options expense     17,350
Amortization of short-term investments (352) (1,145) (183)
Interest on short-term investments 1 55 (55)
Amortization of debt discount and deferred financing costs 2,288 2,339 2,338
Adjustments to fair value of derivatives 3,269 (11,056) (5,458)
Other 3,859 2,267 2,281
Changes in operating assets and liabilities:      
Prepaid expenses and other current assets (2,663) (3,188) (1,551)
Other assets 17 322  
Accounts payable (4,745) 2,223 1,895
Accrued expenses (5,110) 3,489 3,185
Income taxes 155 271 (510)
Other liabilities (385) (354) (708)
Net cash used in operating activities (26,770) (39,330) (18,473)
Cash flows from investing activities:      
Purchases of property and equipment (2) (13) (62)
Purchases of short-term investments (12,390) (41,179) (45,708)
Proceeds from sale of short-term investments 30,600 64,528 59,727
Net cash provided by investing activities 18,208 23,336 13,957
Cash flows from financing activities:      
Repayments of long-term bank debt     (2,251)
Proceeds from issuance of ordinary shares, net of transaction costs 26,691 1,034 433
Net cash provided by / (used in) financing activities 26,691 1,034 (1,818)
Effect of exchange rates on cash and cash equivalents (75) (61) (50)
Net increase / (decrease) in cash, cash equivalents and restricted cash 18,054 (15,021) (6,384)
Cash, cash equivalents and restricted cash, at beginning of period 6,105 21,126 27,510
Cash, cash equivalents and restricted cash, at end of period 24,159 6,105 21,126
Supplemental Disclosure of Cash Flow Information:      
Income tax paid—U.S. 220 401 821
Interest paid     22
Non-cash proceeds - Pfizer Promissory Note 20,000    
Exchangeable Notes      
Adjustments to reconcile net loss to cash used in operating activities:      
Interest on notes - non-cash 723 $ 811 $ 819
Promissory Note      
Adjustments to reconcile net loss to cash used in operating activities:      
Interest on notes - non-cash $ 300